Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries, a text-based module, and a downloadable slideset.
Read this commentary from Maria E. Arcila, MD, on the recommendations for testing for NRG1 fusions in patients with solid tumors.
Expert commentary by Joshua Sabari, MD, on the role of NRG1 fusions in solid tumors and the emerging targeted therapies for patients harboring this oncogenic alteration.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.